Effects of tumor necrosis factor alpha, interferon alpha and interferon gamma on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation
- PMID: 1511460
- PMCID: PMC11038614
- DOI: 10.1007/BF01789332
Effects of tumor necrosis factor alpha, interferon alpha and interferon gamma on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation
Abstract
The potential role of tumor necrosis factor alpha (TNF alpha), interferon alpha (IFN alpha) and interferon gamma (IFN gamma) in the therapy of non-lymphoid leukemia was studied in ten non-lymphoid leukemia cell lines. All three cytokines tested inhibited the growth of the cell lines. However, a high degree of variability in susceptibility to cytotoxic/cytostatic effect of the cytokines was found among individual cell lines. Some cell lines were sensitive to the antiproliferative action of only one of the cytokines tested, but were resistant to the others. Combinations of two cytokines had additive or synergistic effects and inhibited cell growth to a greater extent than did the individual cytokines alone. In addition to the growth-inhibitory effect, the cytokines induced an apparent cell differentiation. The differentiation of the two most sensitive cell lines, EoL-1 and PL-21, was confirmed using the nitroblue tetrazolium reduction test, by changes in cell morphology, immunophenotype marker profiles and by changes in c-myb expression. Furthermore, we showed that even in the cell lines relatively resistant to the antiproliferative effect of cytokines, such as cell line KCL-22, the inhibition of cell growth could be markedly increased with the DNA-topoisomerase-II-targeted drug, doxorubicin. Our data thus suggest that TNF alpha, IFN alpha and IFN gamma together have a potential role in the immunotherapy of non-lymphoid leukemia in terms of their antiproliferative action, and their ability to induce differentiation and to modulate drug sensitivity.
Similar articles
-
Antiproliferative effects of cytokines on squamous cell carcinoma.Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):321-6. doi: 10.1001/archotol.1991.01870150089012. Arch Otolaryngol Head Neck Surg. 1991. PMID: 1900161
-
Synergistic interactions of interleukin 1, interferon-beta, and tumor necrosis factor in terminally differentiating a mouse myeloid leukemic cell line (M1). Evidence that interferon-beta is an autocrine differentiating factor.J Immunol. 1988 Jan 1;140(1):112-9. J Immunol. 1988. PMID: 3275716
-
Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-1.J Biol Response Mod. 1989 Apr;8(2):206-18. J Biol Response Mod. 1989. PMID: 2499665
-
Characterization of the synergistic antiproliferative effects of interferon-gamma and tumor necrosis factor on human colon carcinoma cell lines.J Interferon Res. 1990 Apr;10(2):129-39. doi: 10.1089/jir.1990.10.129. J Interferon Res. 1990. PMID: 2111352
-
Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines.Pancreas. 1988;3(2):180-8. doi: 10.1097/00006676-198804000-00012. Pancreas. 1988. PMID: 3131759
Cited by
-
Modulation of mdr1 expression by cytokines in human colon carcinoma cells: an approach for reversal of multidrug resistance.Br J Cancer. 1996 Nov;74(9):1384-91. doi: 10.1038/bjc.1996.553. Br J Cancer. 1996. PMID: 8912533 Free PMC article.
-
Cytokine-mediated reversal of multidrug resistance.Cytotechnology. 1998 Sep;27(1-3):271-82. doi: 10.1023/A:1008089512856. Cytotechnology. 1998. PMID: 19002798 Free PMC article.
-
Systemic use of tumor necrosis factor alpha as an anticancer agent.Oncotarget. 2011 Oct;2(10):739-51. doi: 10.18632/oncotarget.344. Oncotarget. 2011. PMID: 22036896 Free PMC article. Review.
References
-
- Abbuzzese JL, Levin B, Ajani JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human γ-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989;49:4057. - PubMed
-
- Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at topoisomerase II. Cancer Res. 1987;47:2403. - PubMed
-
- Ariyasu T, Kimura N, Kikuchi M, Kohno K, Sugamura K, Watanabe T, Minowada J. Induced natural killer-like cytotoxic function in the TCR δ-1 positive human leukemic T-cell lines. Leukemia. 1991;5:807. - PubMed
-
- Beran M, Anderson BS, Kelleher P, Whalen K, McCredie K, Gutterman J. Diversity of the effect of recombinant tumor necrosis factor α and β on human myelogenous leukemia cell lines. Blood. 1987;69:721. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources